Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.
atezolizumab
bevacizumab
hepatocellular carcinoma
real-world data
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Jun 2021
03 Jun 2021
Historique:
received:
25
04
2021
revised:
24
05
2021
accepted:
02
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Atezolizumab plus bevacizumab was approved for patients with hepatocellular carcinoma (HCC). Although clinical trials have revealed its efficacy, the outcomes in the real-world clinical practice are unclear. We retrospectively evaluated the efficacy and safety of atezolizumab plus bevacizumab for HCC. This is a multicenter study conducted between November 2020 and March 2021. Among the 61 patients, 51 were assessed for progression-free survival (PFS), therapeutic response, and adverse events (AEs). The median PFS was 5.4 months. The objective response rate (ORR) was 35.3%. The disease control rate (DCR) was 86.3%. The incidence rates of AEs at any grade and grade >3 were 98.0% and 29.4%, respectively. The most frequent AE at any grade and grade >3 was hepatic disorder. In patients with a previous history of molecular targeted agent (MTA) or the degree of albumin-bilirubin (ALBI) grade, there were no significant differences in the PFS, ORR, DCR, and incidence rates of AEs. The study demonstrated that atezolizumab plus bevacizumab was effective and safe for patients with HCC even in the real-world setting including patients with a previous MTA history or other than ALBI grade 1.
Sections du résumé
BACKGROUND
BACKGROUND
Atezolizumab plus bevacizumab was approved for patients with hepatocellular carcinoma (HCC). Although clinical trials have revealed its efficacy, the outcomes in the real-world clinical practice are unclear. We retrospectively evaluated the efficacy and safety of atezolizumab plus bevacizumab for HCC.
MATERIALS AND METHODS
METHODS
This is a multicenter study conducted between November 2020 and March 2021. Among the 61 patients, 51 were assessed for progression-free survival (PFS), therapeutic response, and adverse events (AEs).
RESULTS
RESULTS
The median PFS was 5.4 months. The objective response rate (ORR) was 35.3%. The disease control rate (DCR) was 86.3%. The incidence rates of AEs at any grade and grade >3 were 98.0% and 29.4%, respectively. The most frequent AE at any grade and grade >3 was hepatic disorder. In patients with a previous history of molecular targeted agent (MTA) or the degree of albumin-bilirubin (ALBI) grade, there were no significant differences in the PFS, ORR, DCR, and incidence rates of AEs.
CONCLUSION
CONCLUSIONS
The study demonstrated that atezolizumab plus bevacizumab was effective and safe for patients with HCC even in the real-world setting including patients with a previous MTA history or other than ALBI grade 1.
Identifiants
pubmed: 34205099
pii: cancers13112786
doi: 10.3390/cancers13112786
pmc: PMC8199943
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Oncol Rep. 2017 Aug;38(2):899-907
pubmed: 28627705
Liver Cancer. 2020 Jun;9(3):338-357
pubmed: 32647635
Future Oncol. 2021 Jun;17(17):2243-2256
pubmed: 33663220
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
Theranostics. 2021 Jan 1;11(5):2098-2107
pubmed: 33500713
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
JHEP Rep. 2020 Aug 11;2(6):100170
pubmed: 33205034
Cancers (Basel). 2020 Apr 19;12(4):
pubmed: 32325921
Liver Cancer. 2020 Dec;9(6):629-639
pubmed: 33442537
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Cancer. 2019 Oct 1;125(19):3312-3319
pubmed: 31290997
Eur J Cancer. 2016 Jul;62:138-45
pubmed: 27237360
Nature. 2021 Apr;592(7854):444-449
pubmed: 33762736
Dig Dis. 2012;30(6):598-602
pubmed: 23258101
Cancers (Basel). 2021 Jan 11;13(2):
pubmed: 33440630
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Liver Cancer. 2020 Jan;9(1):1-5
pubmed: 32071904
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Nature. 2021 Apr;592(7854):450-456
pubmed: 33762733
Jpn J Clin Oncol. 2020 Jul 9;50(7):800-809
pubmed: 32083295
Cancers (Basel). 2020 Jul 11;12(7):
pubmed: 32664489
Cancers (Basel). 2018 Oct 30;10(11):
pubmed: 30380773
Biomedicines. 2021 Jan 21;9(2):
pubmed: 33494227
Mol Cancer. 2019 Nov 6;18(1):155
pubmed: 31690319
J Immunother. 2019 Jan;42(1):29-32
pubmed: 29939877
Adv Hematol. 2018 Nov 1;2018:2458679
pubmed: 30519261